Detected ·
CAST Bio
——
CAST Bio, a drug discovery startup developing next-generation antibody-drug conjugates (ADC) based on proprietary VLK linker technology, received investment from REALTECH Fund operated by UntroD Capital. The company, established through a spin-off from the National Cancer Center Japan, will advance non-clinical development and organizational structure to create innovative treatments for refractory solid cancers including glioblastoma and pancreatic cancer.
- Website
- —
- —
- Amount
- —
- Stage
- —
- Event
- Funding round
- Detected
- 2026-05-21 10:42:33 UTC
- Signal ID
- 7ad46fa0-25b9-4426-ad51-6f08d9b39c5e
As the API returns it
{
"id": "7ad46fa0-25b9-4426-ad51-6f08d9b39c5e",
"created_at": "2026-05-21T10:42:33.510401Z",
"company_name": "CAST Bio",
"company_website_url": null,
"company_linkedin_url": null,
"event_type": "funding",
"funding_amount": null,
"funding_currency": null,
"funding_stage": null,
"message": "*CAST Bio, a drug discovery startup developing next-generation antibody-drug conjugates (ADC) based on proprietary VLK linker technology, received investment from REALTECH Fund operated by UntroD Capital. The company, established through a spin-off from the National Cancer Center Japan, will advance non-clinical development and organizational structure to create innovative treatments for refractory solid cancers including glioblastoma and pancreatic cancer.*"
}